Key result
Treatment with the oral myeloperoxidase inhibitor AZD4831 for 12 weeks increased left ventricular ejection fraction by 4.3% and reduced NTproBNP levels in patients with dilated cardiomyopathy.
Why the study?
Dilated cardiomyopathy causes heart failure with reduced ejection fraction and increased mortality, but despite evidence of immune activation, anti-inflammatory interventions have not altered disease course.
Does myeloperoxidase inhibition improve systolic left ventricular function in models and patients with dilated cardiomyopathy?
Does myeloperoxidase inhibition improve systolic left ventricular function in models and patients with dilated cardiomyopathy?
Mean Difference: 4.3
Myeloperoxidase inhibition improves ventricular function in dilated cardiomyopathy by lowering systemic vascular resistance, offering a novel therapeutic approach.
No takes yet. Share an insight, caveat, or question.
MPO inhibition may improve LV function in DCM; hypothesis-generating and requires randomized confirmation before practice change.
Geißen et al. (2022) studied Dilated cardiomyopathy with HFrEF (n=5). AZD4831 was evaluated on Change in MRI-based left ventricular ejection fraction (LVEF) at 12 weeks (MD 4.3%). Treatment with the oral myeloperoxidase inhibitor AZD4831 for 12 weeks increased left ventricular ejection fraction by 4.3% and reduced NTproBNP levels in patients with dilated cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: